Fried Shawn, Kozer Eran, Nulman Irena, Einarson Thomas R, Koren Gideon
University of Toronto, Toronto, Ontario, Canada.
Drug Saf. 2004;27(3):197-202. doi: 10.2165/00002018-200427030-00004.
It is widely quoted that women with epilepsy have a higher than baseline risk for giving birth to a child with malformations, independent of the effects of antiepileptic drugs.
To determine, based on available evidence, if epilepsy per se represents a teratogenic risk. To systematically review all studies investigating the occurrence of major malformation rates among children of treated or untreated women with epilepsy and non-exposed controls who do not have epilepsy.
A meta-analysis, using a random effects model, was conducted of all cohort and case-control studies reporting malformation rates in children of women with epilepsy exposed or unexposed to antiepileptic drugs compared with that of children of nonepileptic women. Medline (1966-2001), EMBASE, the Cochrane database as well as REPROTOX (an information system on environmental hazards to human reproduction and development) databases were accessed.
We found ten studies reporting results of untreated epilepsy (n = 400) and their non-epileptic healthy controls (n = 2492). Nine out of ten studies also reported results on 1443 patients exposed to antiepileptic drugs and their 2526 unexposed healthy controls. The risk for congenital malformations in the offspring of women with untreated epilepsy was not higher than among nonepileptic controls (odds ratio [OR] = 1.92; 95% CI 0.92-4.00). There was evidence of publication bias, thus with bias removed the OR was 0.99 (95% CI 0.49-2.01). In contrast, the offspring of epileptic women who received antiepileptic drugs had higher incidences of malformation than controls (OR 3.26; 95% CI 2.15-4.93).
Our study does not support the commonly held view that epilepsy per se represents a teratogenic risk. Our study suggests that this view is the result of a publication bias, with several small (< 100 participants) positive studies leading to a premature conclusion.
广泛引用的观点认为,癫痫女性生育畸形儿的风险高于基线水平,这与抗癫痫药物的影响无关。
基于现有证据确定癫痫本身是否代表致畸风险。系统评价所有调查癫痫女性(无论是否接受治疗)及未患癫痫的未暴露对照所生子女中主要畸形发生率的研究。
采用随机效应模型对所有队列研究和病例对照研究进行荟萃分析,这些研究报告了暴露或未暴露于抗癫痫药物的癫痫女性所生子女与未患癫痫女性所生子女的畸形率。检索了Medline(1966 - 2001年)、EMBASE、Cochrane数据库以及REPROTOX(人类生殖与发育环境危害信息系统)数据库。
我们找到十项研究,报告了未治疗癫痫患者(n = 400)及其非癫痫健康对照(n = 2492)的结果。十项研究中有九项还报告了1443例暴露于抗癫痫药物的患者及其2526例未暴露的健康对照的结果。未治疗癫痫女性后代先天性畸形的风险并不高于非癫痫对照(优势比[OR] = 1.92;95%可信区间0.92 - 4.00)。有证据表明存在发表偏倚,消除偏倚后OR为0.99(95%可信区间0.49 - 2.01)。相比之下,接受抗癫痫药物治疗的癫痫女性后代畸形发生率高于对照(OR 3.26;95%可信区间2.15 - 4.93)。
我们的研究不支持癫痫本身代表致畸风险这一普遍观点。我们的研究表明,这一观点是发表偏倚的结果,一些样本量小(< 100名参与者)的阳性研究导致了过早的结论。